特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
966413

世界のリキッドバイオプシー市場(2020年~2024年)

Global Liquid Biopsy Market 2020-2024

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
世界のリキッドバイオプシー市場(2020年~2024年)
出版日: 2020年09月11日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のリキッドバイオプシーの市場規模は、予測期間中に38%のCAGRで推移して、2020年から2024年の間に40億2000万米ドル成長する見込みです。同市場は、癌の発生率の増加と癌の早期発見への注目の高まりによって推進されています。

当レポートでは、リキッドバイオプシー市場を調査し、市場概要、市場の成長要因および阻害要因の分析、技術別・地域別の市場規模の推移と予測、ベンダー分析、市場機会など、包括的な情報を提供しています。

目次

エグゼクティブサマリー

市場情勢

市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模2019
  • 市場の見通し:2019年から2024年の予測

ファイブフォース分析

技術別市場セグメンテーション

  • 市場セグメンテーション
  • 技術別比較
  • CTCとctDNA-市場規模と予測(2019年-2024年)
  • エクソソームとRNA-市場規模と予測(2019年-2024年)
  • 技術別市場機会

顧客情勢

地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米-市場規模と予測(2019年-2024年)
  • 欧州-市場規模と予測(2019年-2024年)
  • アジア-市場規模と予測(2019年-2024年)
  • その他の地域-市場規模と予測(2019年-2024年)
  • 主要な主要国
  • 地域の市場機会
  • 市場の推進力
  • 市場の課題
  • 市場動向

ベンダー情勢

  • 概要
  • ベンダー情勢
  • 創造的破壊の状況

ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • ANGLE Plc
  • Biocept Inc.
  • Bio-Techne Corp.
  • CIRCULOGENE
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health Inc.
  • LungLife AI Inc.
  • Myriad Genetics Inc.
  • QIAGEN NV
  • SAGA Diagnostics AB

付録

目次
Product Code: IRTNTR45000

Technavio has been monitoring the liquid biopsy market and it is poised to grow by $ 4.02 bn during 2020-2024, progressing at a CAGR of 38% during the forecast period. Our reports on liquid biopsy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing incidence of cancer and increasing focus on early detection of cancer. In addition, increasing funding for liquid biopsy is anticipated to boost the growth of the market as well.

The liquid biopsy market analysis includes the technology segment and geographical landscapes.

Technavio's ‘liquid biopsy market ’ is segmented as below:

By Technology

  • CTC and ctDNA
  • Exosome and RNA

By Geographic Landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the growing focus on personalized medicine for cancer care as one of the prime reasons driving the liquid biopsy market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our liquid biopsy market covers the following areas:

  • Liquid biopsy market sizing
  • Liquid biopsy market forecast
  • Liquid biopsy market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading liquid biopsy market vendors that include ANGLE Plc, Biocept Inc., Bio-Techne Corp., CIRCULOGENE, F. Hoffmann-La Roche Ltd., Guardant Health Inc., LungLife AI Inc., Myriad Genetics Inc., QIAGEN NV, and SAGA Diagnostics AB. Also, the liquid biopsy market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Technology

  • Market segments
  • Comparison by Technology
  • CTC and ctDNA - Market size and forecast 2019-2024
  • Exosome and RNA - Market size and forecast 2019-2024
  • Market opportunity by Technology

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • ANGLE Plc
  • Biocept Inc.
  • Bio-Techne Corp.
  • CIRCULOGENE
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health Inc.
  • LungLife AI Inc.
  • Myriad Genetics Inc.
  • QIAGEN NV
  • SAGA Diagnostics AB

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Technology - Market share 2019-2024 (%)
  • 22: Comparison by Technology
  • 23: CTC and ctDNA - Market size and forecast 2019-2024 ($ million)
  • 24: CTC and ctDNA - Year-over-year growth 2019-2024 (%)
  • 25: Exosome and RNA - Market size and forecast 2019-2024 ($ million)
  • 26: Exosome and RNA - Year-over-year growth 2019-2024 (%)
  • 27: Market opportunity by Technology
  • 28: Customer landscape
  • 29: Market share by geography 2019-2024 (%)
  • 30: Geographic comparison
  • 31: North America - Market size and forecast 2019-2024 ($ million)
  • 32: North America - Year-over-year growth 2019-2024 (%)
  • 33: Europe - Market size and forecast 2019-2024 ($ million)
  • 34: Europe - Year-over-year growth 2019-2024 (%)
  • 35: Asia - Market size and forecast 2019-2024 ($ million)
  • 36: Asia - Year-over-year growth 2019-2024 (%)
  • 37: ROW - Market size and forecast 2019-2024 ($ million)
  • 38: ROW - Year-over-year growth 2019-2024 (%)
  • 39: Key leading countries
  • 40: Market opportunity by geography ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: ANGLE Plc - Overview
  • 48: ANGLE Plc - Business segments
  • 49: ANGLE Plc - Key offerings
  • 50: ANGLE Plc - Key customers
  • 51: ANGLE Plc - Segment focus
  • 52: Biocept Inc. - Overview
  • 53: Biocept Inc. - Business segments
  • 54: Biocept Inc. - Key offerings
  • 55: Biocept Inc. - Key customers
  • 56: Biocept Inc. - Segment focus
  • 57: Bio-Techne Corp. - Overview
  • 58: Bio-Techne Corp. - Business segments
  • 59: Bio-Techne Corp. - Key offerings
  • 60: Bio-Techne Corp. - Key customers
  • 61: Bio-Techne Corp. - Segment focus
  • 62: CIRCULOGENE - Overview
  • 63: CIRCULOGENE - Product and service
  • 64: CIRCULOGENE - Key offerings
  • 65: CIRCULOGENE - Key customers
  • 66: CIRCULOGENE - Segment focus
  • 67: F. Hoffmann-La Roche Ltd. - Overview
  • 68: F. Hoffmann-La Roche Ltd. - Business segments
  • 69: F. Hoffmann-La Roche Ltd. - Key offerings
  • 70: F. Hoffmann-La Roche Ltd. - Key customers
  • 71: F. Hoffmann-La Roche Ltd. - Segment focus
  • 72: Guardant Health Inc. - Overview
  • 73: Guardant Health Inc. - Business segments
  • 74: Guardant Health Inc. - Key offerings
  • 75: Guardant Health Inc. - Key customers
  • 76: Guardant Health Inc. - Segment focus
  • 77: LungLife AI Inc. - Overview
  • 78: LungLife AI Inc. - Product and service
  • 79: LungLife AI Inc. - Key offerings
  • 80: LungLife AI Inc. - Key customers
  • 81: LungLife AI Inc. - Segment focus
  • 82: Myriad Genetics Inc. - Overview
  • 83: Myriad Genetics Inc. - Business segments
  • 84: Myriad Genetics Inc. - Key offerings
  • 85: Myriad Genetics Inc. - Key customers
  • 86: Myriad Genetics Inc. - Segment focus
  • 87: QIAGEN NV - Overview
  • 88: QIAGEN NV - Business segments
  • 89: QIAGEN NV - Key offerings
  • 90: QIAGEN NV - Key customers
  • 91: QIAGEN NV - Segment focus
  • 92: SAGA Diagnostics AB - Overview
  • 93: SAGA Diagnostics AB - Product and service
  • 94: SAGA Diagnostics AB - Key offerings
  • 95: SAGA Diagnostics AB - Key customers
  • 96: SAGA Diagnostics AB - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.